Genomic & Biopharma News

Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat
Could Dupixent end up beating Novartis’ speedy Cosentyx launch? That would be a feat, given that Cosentyx, a next-gen psoriasis therapy, raced to blockbuster status after its 2015 rollout. But so far, the numbers on Sanofi's new eczema med look even better, the company says.
Fierce Pharma, 2017-07-31 13:53:01

Biogen poaches Pfizer vet Villalobos for biotherapeutics lead
Biogen has taken Anabella Villalobos, Ph.D., away from Pfizer and placed her as its new SVP of biotherapeutic and medicinal sciences.
Fierce Biotech, 2017-07-31 13:52:29

Newly identified biomarkers could lead to better therapies for cystic fibrosis
Researchers have identified two new biological markers of cystic fibrosis (CF), a genetic disease which affects children and young adults, leaving them with lifelong health complications including digestive problems and persistent lung infections.
News Medical Life Sciences, 2017-07-31 13:50:19

PellePharm readies hedgehog inhibitor for phase 3, plans series C after claiming success in small rare disease study
PellePharm is gearing up for talks with the FDA about its phase 3 program. The biotech stepped up plans to get the late-stage study underway in the first half of next year after getting a look at data from a phase 2 trial of its hedgehog inhibitor in patients with Gorlin syndrome.
Fierce Biotech, 2017-07-31 13:33:24

After Mystic setback, MedImmune takes on new FDA, academic immuno-oncology execs
AstraZeneca and MedImmune, still reeling from a combo survival failure of its new immuno-oncology meds lung cancer, have hired a clutch of new cancer R&D execs.
Fierce Biotech, 2017-07-31 13:31:19

Battered AstraZeneca hits new frontier with Imfinzi lung cancer maintenance 'breakthrough'
After a disappointing combo announcement that knocked nearly 16% off of shares, AstraZeneca’s immuno-oncology portfolio needed a boost—and it got one Monday. The FDA handed the battered company a breakthrough designation for its PD-L1 med, Imfinzi, as a maintenance therapy in surgery-ineligible non-small cell lung cancer patients.
Fierce Pharma, 2017-07-31 12:59:59

Aerie swoops on DSM tech for eye disease candidates
Aerie Pharma—just months away from a possible approval for its lead glaucoma drug—is hoping to unlock the potential of a key pipeline compound with help from Netherlands company Royal DSM.
Fierce Biotech, 2017-07-31 12:32:39

Redx sells cancer drug to Loxo to escape debt crisis 
Redx Pharma has sold its BTK inhibitor program to Loxo Oncology for $40 million (€34 million) upfront to pay off an outstanding loan. The deal was put together by the insolvency firm Liverpool council called in to recoup the loan and rescue Redx.
Fierce Biotech, 2017-07-31 12:31:55

Integrating RNA sequencing into neuro-oncology practice
Malignant tumors of the central nervous system (CNS) cause substantial morbidity and mortality, yet efforts to optimize chemo- and radiotherapy have largely failed to improve dismal prognoses. Over the past decade, RNA sequencing (RNA-seq) has emerged as a powerful tool to comprehensively characterize the transcriptome of CNS tumor cells in one high-throughput step, leading to ...
Transcriptome Research & Industry News, 2017-07-31 12:21:50